Pressmeddelanden från Genmab

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Transactions in Connection with Share Buy-back Program 02 mar 22:53

Correction to Company Announcement No. 13 of March 2, 2026 02 mar 20:58

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 02 mar 15:04

Transactions in Connection with Share Buy-back Program 27 feb 21:23

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 27 feb 21:21

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab 25 feb 16:27

Genmab to Participate in Upcoming Investor Conferences 24 feb 21:20

Capital Increase in Genmab as a Result of Employee Warrant Exercise 23 feb 15:33

Transactions in Connection with Share Buy-back Program 20 feb 16:05

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 18 feb 15:09

Notice to Convene the Annual General Meeting of Genmab A/S 17 feb 21:14

Genmab Announces Initiation of Share Buy-Back Program 17 feb 17:23

Genmab Files Annual Report with the U.S. Securities and Exchange Commission 17 feb 17:01

Genmab Publishes 2025 Annual Report 29 jan 18:49

Grant of Restricted Stock Units and Warrants to Employees in Genmab 21 jan 12:23

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 16 jan 19:30

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)07 jan 15:00

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence 05 jan 13:58

Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference 29 dec 2025 14:10

Genmab Portfolio Prioritization Update 12 dec 2025 07:35

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period 11 dec 2025 08:00

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting 08 dec 2025 22:30

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)07 dec 2025 13:50

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma 06 dec 2025 15:30

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)03 dec 2025 21:03

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes 01 dec 2025 22:24

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons 24 nov 2025 13:00

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami 20 nov 2025 21:02

Grant of Restricted Stock Units and Warrants to Employees in Genmab 19 nov 2025 18:56

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 18 nov 2025 22:01

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility 18 nov 2025 20:58

Capital Increase in Genmab as a Result of Employee Warrant Exercise 18 nov 2025 17:30

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma 10 nov 2025 16:51

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes 10 nov 2025 13:12

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility 06 nov 2025 17:02

Genmab Announces Financial Results for the Nine Months of 2025 05 nov 2025 18:58

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London 03 nov 2025 15:05

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting 21 okt 2025 14:12

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.18 okt 2025 12:00

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer 14 okt 2025 12:23

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 29 sep 2025 07:08

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model 26 sep 2025 01:14

Grant of Restricted Stock Units and Warrants to Employees in Genmab 23 sep 2025 15:18

Major Shareholder Announcement 09 sep 2025 20:57

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 09 sep 2025 20:54

Capital Increase in Genmab as a Result of Employee Warrant Exercise 03 sep 2025 14:30

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)26 aug 2025 15:31

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference 26 aug 2025 14:00

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)12 aug 2025 20:36

Capital Increase in Genmab as a Result of Employee Warrant Exercise 07 aug 2025 17:08

Genmab Announces Financial Results for the First Half of 2025 07 aug 2025 16:30

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) 16 jul 2025 12:29

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025 01 jul 2025 14:00

Genmab Announces Changes to its Executive Committee 30 jun 2025 15:30

Completion of Share Buy-back Program 23 jun 2025 14:19

Transactions in Connection with Share Buy-back Program 17 jun 2025 19:34

Capital Increase in Genmab as a Result of Employee Warrant Exercise 17 jun 2025 17:37

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 16 jun 2025 15:28

Transactions in Connection with Share Buy-back Program 15 jun 2025 11:00

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)12 jun 2025 19:08

Grant of Restricted Stock Units and Warrants to Employees in Genmab 10 jun 2025 13:23

Transactions in Connection with Share Buy-back Program 02 jun 2025 20:30

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial 02 jun 2025 14:03

Transactions in Connection with Share Buy-back Program 27 maj 2025 15:55

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference 26 maj 2025 14:30

Transactions in Connection with Share Buy-back Program 22 maj 2025 23:05

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting 21 maj 2025 16:02

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference 20 maj 2025 18:01

Capital Increase in Genmab as a Result of Employee Warrant Exercise 19 maj 2025 15:08

Transactions in Connection with Share Buy-back Program 14 maj 2025 16:15

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress 12 maj 2025 14:51

Transactions in Connection with Share Buy-back Program 08 maj 2025 17:01

Genmab Announces Financial Results for the First Quarter of 2024 05 maj 2025 14:23

Transactions in Connection with Share Buy-back Program 02 maj 2025 02:14

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)28 apr 2025 14:16

Transactions in Connection with Share Buy-back Program 22 apr 2025 13:23

Transactions in Connection with Share Buy-back Program 15 apr 2025 12:22

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 14 apr 2025 14:42

Transactions in Connection with Share Buy-back Program 10 apr 2025 18:20

Genmab A/S Share Capital Reduction 07 apr 2025 13:43

Transactions In Connection with Share Buy-back Program 01 apr 2025 21:53

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons 31 mar 2025 17:20

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer 31 mar 2025 14:18

Transactions in connection with share buy-back program 27 mar 2025 13:00

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy 25 mar 2025 22:28

Genmab Announces Initiation of Share Buy-Back Program 22 mar 2025 04:29

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. 17 mar 2025 17:19

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer 12 mar 2025 19:19

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 12 mar 2025 19:13

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab 12 mar 2025 15:23

Passing of Genmab A/S’ Annual General Meeting 10 mar 2025 15:13

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 04 mar 2025 17:58

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 28 feb 2025 22:04

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons 28 feb 2025 22:00

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab 25 feb 2025 20:30

Capital Increase in Genmab as a Result of Employee Warrant Exercise 20 feb 2025 14:00

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma 19 feb 2025 15:14

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference 13 feb 2025 12:00

Notice to Convene the Annual General Meeting of Genmab A/S 12 feb 2025 19:14

Genmab Files Annual Report with the U.S. Securities and Exchange Commission